secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcturus Therapeutics Holdings Inc. (ARCT)
CIK:        0001768224
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001193805-23-001174
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcturus' JV ARCALIS awarded $115M in Japanese government grants; achieves $17.5M CSL flu milestone
--------------------------------------------------------------------------------

- ARCALIS, Arcturus' 49%-owned joint venture, receives $115M in two grants to build a cGMP mRNA factory in Minamisoma, Japan.
- LUNAR-FLU program achieves $17.5M development milestone from CSL Seqirus; funds used for flu program development activities.
- The factory will support cGMP production of mRNA drug substance and drug product for Arcturus' STARR mRNA vaccines.
- CSL Seqirus is exclusive global licensee for mRNA vaccines against COVID-19, flu, and three other respiratory diseases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768224/000119380523001174/0001193805-23-001174-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768224/000119380523001174/e618874_8k-arct.htm
  HTML page:      https://secwatch.observer/filing/0001193805-23-001174

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer